Image de couverture de livre

Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Sebastian Schneeweiss
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data
par: Martin Russek, et autres
Publié: (2025)

A Framework for Assessing the Viability of External Control for a Single‐Arm Trial
par: Victor A. Kiri
Publié: (2026)

Post hoc Population Standardization of Trial Emulation Studies in Claims Data: An RCT ‐ DUPLICATE Analysis
par: Phyo Than Htoo, et autres
Publié: (2026)

A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post‐Cataract Surgery Inflammation
par: Yuanyuan Zhao, et autres
Publié: (2025)

Corrections to “Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions”
Publié: (2024)

Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Publié: (2024)

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data
par: Francesco Pignatti, et autres
Publié: (2026)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
par: Emily K. Acton, et autres
Publié: (2024)

Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial
par: Andrew H. Ko, et autres
Publié: (2024)

Emulating Comparative Oncology Trials With Real‐World Evidence Studies ( ENCORE ): Process Development and Methodological Considerations for Oncology Real‐World Data
par: Janick Weberpals, et autres
Publié: (2026)

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
par: Sumit Bhatnagar, et autres
Publié: (2024)

Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer
par: Abhishek G. Sathe, et autres
Publié: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
par: Jatinder Kaur Mukker, et autres
Publié: (2025)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
par: Benjamin Rich, et autres
Publié: (2025)

All that Glitters Is not Gold: Type‐I Error Controlled Variable Selection from Clinical Trial Data
par: Manuela R. Zimmermann, et autres
Publié: (2024)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
par: Titia Q. Ruijs, et autres
Publié: (2024)

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP
par: Munjal Patel, et autres
Publié: (2025)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
par: Sébastien Taillemite, et autres
Publié: (2026)

How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study
par: Olha Shuklinova, et autres
Publié: (2024)

Building Pharmacoequity through Student and Trainee Education, Service, and Global Outreach
par: Chazmyn Riley, et autres
Publié: (2026)

Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective
par: Mohamed‐Eslam F. Mohamed, et autres
Publié: (2024)

Frequency and Nature of Generic “Design Around” of Brand‐Name Patents in the United States
par: Janet Freilich, et autres
Publié: (2025)

Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk
par: Jean Dai, et autres
Publié: (2024)

Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
par: Enrico Costa, et autres
Publié: (2026)

Methodology for Good Machine Learning with Multi‐Omics Data
par: Thibaud Coroller, et autres
Publié: (2024)

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib
par: Devasha Redhi, et autres
Publié: (2026)

AI ‐Enabled Precision Dosing in Pediatrics: Enhancing Model‐Informed Decision Making
par: Kei Irie, et autres
Publié: (2026)

Tailoring Drug Therapy: Bridging Data Science and Clinical Reality
par: Karen Rowland Yeo
Publié: (2026)

Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence
par: Gorana Capkun, et autres
Publié: (2025)

Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
par: Xiaozhi Liao, et autres
Publié: (2024)

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models
par: Eunjin Hong, et autres
Publié: (2025)

Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials
par: Florian Lemaitre, et autres
Publié: (2024)

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
par: Hung‐Kuan Yen, et autres
Publié: (2025)

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data
par: Kaisa Litonius, et autres
Publié: (2024)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
par: Gerald Chun‐To So, et autres
Publié: (2025)

Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine
par: Liang Zhao, et autres
Publié: (2024)

Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis
par: Pieter A. Annema, et autres
Publié: (2024)

Minimizing Racial Algorithmic Bias when Predicting Electronic Health Record Data Completeness
par: Priyanka Anand, et autres
Publié: (2025)

Long‐Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and Structural Variants
par: Sumudu Rangika Samarasinghe, et autres
Publié: (2025)

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers
par: Marella Cornelia Elizabeth van Ruissen, et autres
Publié: (2025)